← All trials
NCT05894564
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 25, 2022
- Primary completion
- Feb 27, 2023
- Completion date
- May 30, 2023
- First posted
- Jun 8, 2023
- Last posted
- Jul 6, 2023
- Enrollment
- 1188
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Duke UniversityLead sponsor
- Duke UniversityOverall official - principal investigator
- Duke UniversityOverall official - principal investigator
- Duke UniversitySponsor investigator
- Vanderbilt UniversityCollaborator
- National Center for Advancing Translational Science (NCATS)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.